Ipamorelin vs CJC-1295: Research Comparison | Peptide Intel Hub

Ipamorelin is a pentapeptide selective agonist at the ghrelin receptor (also known as the GHS-R1a or growth-hormone secretagogue receptor). Its proposed mechanism in research models is selective ghrelin-axis activation without meaningful effect on cortisol, prolactin or aldosterone release — which distinguishes it from earlier ghrelin-receptor agonists.

CJC-1295 is a 30-residue GHRH analogue acting at the GHRH receptor. The 'with DAC' variant adds a drug-affinity-complex modification that promotes covalent albumin binding and substantially extends the half-life; the 'no DAC' variant is the unmodified short analogue.

Ipamorelin is selective for the ghrelin receptor — the selectivity profile is the engineering advantage over earlier ghrelin-receptor agonists like GHRP-6 or GHRP-2 which carry additional off-target effects.

CJC-1295 is selective for the GHRH receptor. The complementary receptor profile to ipamorelin is the reason the two are typically paired in research panels — combined ghrelin-axis and GHRH-axis activation produces a synergistic GH-release signal in research models.

Ipamorelin has a short native half-life — research cadences in published preclinical work are typically daily or sub-daily.

CJC-1295 no DAC sits in a similar daily-cadence window; CJC-1295 with DAC has a substantially longer half-life (multi-day) driven by covalent albumin binding through the DAC modification, suitable for weekly research cadences.

Ipamorelin is used in research models of ghrelin-axis signalling, growth-hormone-axis research and selective-secretagogue-comparator studies. The clean selectivity profile makes it the reference compound for ghrelin-receptor research.

CJC-1295 (with or without DAC) is used in research models of GHRH-axis signalling, growth-hormone-axis research, and as the GHRH-arm in combined-axis panels with ipamorelin. The DAC variant is preferred when a sustained multi-day GHRH-axis signal is the experimental requirement.

Both Ipamorelin and CJC-1295 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Ipamorelin and CJC-1295 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose ipamorelin when the protocol targets selective ghrelin-receptor signalling without GHRP-6 / GHRP-2 off-target effects. Researchers choose CJC-1295 when the protocol targets the GHRH axis specifically — no DAC for a pulsatile profile, with DAC for a sustained multi-day profile. Matched panels of ipamorelin + CJC-1295 are one of the most common growth-hormone-secretagogue research designs.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both Ipamorelin and CJC-1295 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Ipamorelin and CJC-1295 are both synthetic peptides that modulate the growth hormone (GH) axis, yet they achieve this through distinct mechanisms and receptor targets (PMID 41490200, PMID 42395176). Ipamorelin is classified as a growth hormone secretagogue (GHS), specifically a GHRP-receptor agonist, and is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) (PMID 9849822, PMID 42395176). It stimulates GH release by acting on a GHRP-like receptor, similar to GHRP-6 (PMID 9849822). CJC-1295, on the other hand, is a long-acting analog of growth hormone-releasing hormone (GHRH) (PMID 16352683, PMID 42395176). GHRH, a polypeptide synthesized in the hypothalamus, binds to receptors on pituitary somatotropes to promote the synthesis and release of GH (PMID 19386527).

Ipamorelin demonstrates high GH releasing potency and efficacy in both in vitro and in vivo models (PMID 9849822). In vitro, ipamorelin released GH from primary rat pituitary cells with potency and efficacy similar to GHRP-6 (EC50 = 1.3+/-0.4 nmol/l and Emax = 85+/-5% for ipamorelin vs 2.2+/-0.3 nmol/l and 100% for GHRP-6) (PMID 9849822). In pentobarbital anesthetized rats, ipamorelin released GH with potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42 nmol/kg and Emax = 1545+/-250 ng GH/ml for ipamorelin vs 115+/-36 nmol/kg and 1167+/-120 ng GH/ml for GHRP-6) (PMID 9849822). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma, also similar to GHRP-6 (PMID 9849822). Notably, ipamorelin was the first GHRP-receptor agonist identified with a selectivity for GH release similar to that of GHRH (PMID 9849822).

A key distinguishing feature of ipamorelin observed in conscious swine studies is its specificity for GH release (PMID 9849822). While both GHRP-6 and GHRP-2 increased plasma levels of ACTH and cortisol, ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation (PMID 9849822). This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release (PMID 9849822). In contrast, CJC-1295 administration in healthy adult humans resulted in sustained, dose-dependent increases in GH and IGF-I levels (PMID 16352683, PMID 19386527). Specific data regarding CJC-1295's direct effects on other pituitary hormones like ACTH and cortisol are not detailed in the provided abstracts, which focus on its GH/IGF-1 axis activation (PMID 19386527).

The pharmacokinetic properties of CJC-1295 highlight its design as a long-acting analog (PMID 16352683). In healthy adult humans, after a single subcutaneous injection of CJC-1295, dose-dependent increases in mean plasma GH concentrations were observed for 6 days or more, and mean plasma IGF-I concentrations increased for 9-11 days (PMID 16352683). The estimated half-life of CJC-1295 in humans was reported to be 5.8-8.1 days (PMID 16352683). After multiple doses, mean IGF-I levels remained above baseline for up to 28 days, indicating a cumulative effect (PMID 16352683).

CJC-1295's prolonged action is attributed to its ability to covalently bind plasma proteins like serum albumin, increasing its half-life compared to the unconjugated peptide (PMID 30938069). These CJC-1295-protein conjugates are capable of stimulating GH production for more than six days in humans after a single administration (PMID 30938069). The provided abstracts do not offer explicit pharmacokinetic data on ipamorelin's half-life or duration of GH stimulation in humans, though animal studies describe daily or thrice-daily administration (PMID 10373343, PMID 39043357). The sustained action of CJC-1295 is a notable difference, allowing for less frequent administration compared to peptides with shorter durations of action (PMID 16352683).

Ipamorelin has shown a range of effects in animal models (PMID 10373343, PMID 38996787, PMID 39043357). In adult female rats, ipamorelin dose-dependently increased longitudinal bone growth rate (LGR) from 42 µm/day in the vehicle group to 44, 50, and 52 µm/day in treatment groups (P<0.0001), and also had a pronounced, dose-dependent effect on body weight gain over 15 days (PMID 10373343). Treatment did not affect total IGF-I levels, IGFBPs, or serum markers of bone formation and resorption in these rats, and pituitary GH content remained unchanged (PMID 10373343). In a cichlid fish (Oreochromis mossambicus), ipamorelin acetate, a ghrelin agonist, led to a significant and dose-dependent rise in food intake and an increase in primary spermatocytes, secondary spermatocytes, and early spermatids (PMID 38996787). Higher doses in fish also increased late spermatids, lobule and lumen areas, and significantly elevated luteinizing hormone (LH) and 11-ketotestosterone (11-KT) concentrations in serum (PMID 38996787).

Both ipamorelin and CJC-1295, often combined, have been investigated for musculoskeletal benefits in preclinical settings (PMID 41476424, PMID 42578445). CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, though these findings are limited to animal studies (PMID 41476424). In ferrets, ipamorelin administered intraperitoneally inhibited cisplatin-induced weight loss on the last day of the delayed phase (48-72 h) by approximately 24% (PMID 39043357). This suggests a potential role in alleviating cachexia in certain animal models. While promising, the claimed benefits of emerging peptide supplements like ipamorelin and CJC-1295 for musculoskeletal recovery and performance remain unsubstantiated by current human trials (PMID 42578445).

In human subjects, CJC-1295 has been shown to result in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was reported as safe and relatively well tolerated, particularly at doses of 30 or 60 µg/kg (PMID 16352683). There was evidence of a cumulative effect after multiple doses (PMID 16352683). However, beyond these initial pharmacokinetic and pharmacodynamic studies, the clinical evidence for the orthopaedic or sports medicine applications of CJC-1295 and ipamorelin in humans is notably scarce (PMID 41476424, PMID 42578445, PMID 42160466). Reviews consistently state that while many unapproved peptides, including CJC-1295 and ipamorelin, show promising outcomes in animal models, rigorous human safety data are scarce (PMID 41966639).

gray market," particularly in sports medicine (PMID 41966639). They are considered investigational and lack sufficient validation for clinical use in many proposed applications (PMID 42862021, PMID 42160466). Therapeutic peptides like ipamorelin and CJC-1295, while categorized as growth hormone secretagogues, require rigorous validation through well-designed clinical trials to establish their safety and efficacy for healthspan extension and other therapeutic applications in aging populations (PMID 42021992). The peptide supplement market for these compounds is experiencing rapid growth driven by marketing claims, but these claims are often unsubstantiated by current human trials (PMID 42578445)."

For many emerging peptides, including ipamorelin and CJC-1295, the absence of efficacy or safety data, especially long-term, is a significant concern (PMID 42578445, PMID 42021992, PMID 41966639). There is potential for serious harm to patients from unapproved peptides (PMID 41966639). Specifically for CJC-1295, female users discussing its use online described concerns relating to gender variations in growth hormone pulses affecting dosage, cycling, and long-term consequences (PMID 26771670). While a study of CJC-1295 in healthy adults reported no serious adverse reactions and being relatively well tolerated at certain doses, this was within a controlled study design (PMID 16352683). Broader concerns regarding unregulated supply chains, product mislabeling, and contamination exacerbate the dangers of these substances (PMID 41880199).

The broader class of performance-enhancing peptides modulating the GH-IGF-1 axis, which includes CJC-1295 and ipamorelin, has reported adverse effects spanning endocrine and metabolic disturbances such as prolactin and cortisol elevations, appetite changes, and dysglycemia (PMID 42395176). Fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions have also been reported (PMID 42395176). Some peptides, though not specifically ipamorelin or CJC-1295 in the provided abstracts, have been associated with significant risks including congestive heart failure and metabolic dysfunction like insulin resistance (PMID 42578445). These represent experimental substances with poorly defined long-term risks (PMID 41880199). The critical lack of evidence supports a cautious approach to their clinical use, with clinical use largely confined to approved metabolic agents for indicated conditions or rigorously designed research protocols (PMID 41476424, PMID 42160466).

• Ipamorelin, the first selective growth hormone secretagogue. — European journal of endocrinology (1998). PMID 9849822
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.) (2026). PMID 41966639
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026). PMID 41490200
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine (2026). PMID 41476424
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine (2026). PMID 42578445
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. — Frontiers in aging (2026). PMID 42021992
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — The Journal of sports medicine and physical fitness (2026). PMID 41880199
• Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (1999). PMID 10373343
• The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. — Animal reproduction science (2024). PMID 38996787
• The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. — Physiology & behavior (2024). PMID 39043357
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. — The Journal of clinical endocrinology and metabolism (2006). PMID 16352683
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. — Substance use & misuse (2016). PMID 26771670
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. — Drug testing and analysis (2019). PMID 30938069
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (2009). PMID 19386527
• Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. — Sexual medicine reviews (2026). PMID 42862021
• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. — JBJS reviews (2026). PMID 42160466
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. — Frontiers in endocrinology (2026). PMID 42395176

Both Ipamorelin and CJC-1295 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.